These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 34329334)

  • 21. HPV DNA testing with cytology triage in cervical cancer screening: Influence of revealing HPV infection status.
    Richardson LA; El-Zein M; Ramanakumar AV; Ratnam S; Sangwa-Lugoma G; Longatto-Filho A; Cardoso MA; Coutlée F; Franco EL;
    Cancer Cytopathol; 2015 Dec; 123(12):745-54. PubMed ID: 26230283
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy of careHPV™ human papillomavirus screening versus conventional cytology tests for the detection of precancerous and cancerous cervical lesions among women living with HIV-1 in Lao People's Democratic Republic.
    Paboriboune P; Phongsavan K; Arounlangsy P; Flaissier B; Aphayarath O; Phimmasone P; Banchongphanith K; Xayaovong M; Jourdain G; Schott AM; Saadatian-Elahi M; Magaud L; Klich A; Ngo-Giang-Huong N; Heard I; Rabilloud M; Picot VS; Longuet C
    Cancer Med; 2022 May; 11(9):1984-1994. PubMed ID: 35257506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective One Year Follow Up of HIV Infected Women Screened for Cervical Cancer Using Visual Inspection with Acetic Acid, Cytology and Human Papillomavirus Testing in Johannesburg South Africa.
    Firnhaber C; Goeieman B; Faesen M; Levin S; Williams S; Rameotshela S; Swarts A; Michelow P; Omar T; Williamson AL; Allan B; Schnippel K; Smith JS
    PLoS One; 2016; 11(1):e0144905. PubMed ID: 26730710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Determination of the diagnostic accuracy of testing for high-risk (HR) human papillomavirus (HPV) types 16, 18 and 45 in precancerous cervical lesions: preliminary data.
    Tiews S; Steinberg W; Schneider W; Hanrath C
    J Clin Virol; 2009 Nov; 46 Suppl 3():S11-5. PubMed ID: 20129068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Costs and Cost Effectiveness of Three Approaches for Cervical Cancer Screening among HIV-Positive Women in Johannesburg, South Africa.
    Lince-Deroche N; Phiri J; Michelow P; Smith JS; Firnhaber C
    PLoS One; 2015; 10(11):e0141969. PubMed ID: 26569487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I of the DiaVACCS screening trial: Study design, methods, population demographics and baseline results.
    Dreyer G; Snyman LC; Van der Merwe FH; Richter KL; Dreyer GJ; Visser C; Botha MH
    S Afr Med J; 2022 Jul; 112(7):478-486. PubMed ID: 36217858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Searching for an ideal cervical cancer screening model to reduce false-negative errors in a country with high prevalence of cervical cancer.
    Song T; Seong SJ; Lee SK; Kim BR; Ju W; Kim KH; Nam K; Sim JC; Kim TJ
    J Obstet Gynaecol; 2020 Feb; 40(2):240-246. PubMed ID: 31340702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved abnormal Pap smear triage using cervical cancer biomarkers.
    Killeen JL; Dye T; Grace C; Hiraoka M
    J Low Genit Tract Dis; 2014 Jan; 18(1):1-7. PubMed ID: 23760145
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of abnormal cervical and vaginal cytology among women over age 65 years living with human immunodeficiency virus.
    Stewart KA; Allen SM; Chesnokova AE; Syed F; Levison JE
    Am J Obstet Gynecol; 2020 May; 222(5):486.e1-486.e10. PubMed ID: 31678094
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human papillomavirus infection in HIV-1 infected women in Catalonia (Spain): implications for prevention of cervical cancer.
    Stuardo V; Agustí C; Godinez JM; Montoliu A; Torné A; Tarrats A; Alcalde C; Martín D; Fernández-Montoli E; Vanrell C; Solé J; Canet Y; Marqueta JM; Mohamed J; Cuenca I; Lonca M; Sirera G; Ferrer E; Domingo P; Lloveras B; Miro JM; De Sanjosé S; Casabona J
    PLoS One; 2012; 7(10):e47755. PubMed ID: 23118894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Performance of HPV testing, Pap smear and VIA in women attending cervical cancer screening in Kilimanjaro region, Northern Tanzania: a cross-sectional study nested in a cohort.
    Mremi A; Mchome B; Mlay J; Schledermann D; Blaakær J; Rasch V
    BMJ Open; 2022 Oct; 12(10):e064321. PubMed ID: 36316070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papilloma virus testing knowledge and attitudes among women attending colposcopy clinic with ASCUS/LGSIL pap smears.
    Le T; Hicks W; Menard C; Boyd D; Hewson T; Hopkins L; Kee Fung MF
    J Obstet Gynaecol Can; 2004 Sep; 26(9):788-92. PubMed ID: 15361273
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Urinary HPV DNA testing as a tool for cervical cancer screening in women who are reluctant to have a Pap smear in France.
    Lefeuvre C; Pivert A; Guillou-Guillemette HL; Lunel-Fabiani F; Veillon P; Le Duc-Banaszuk AS; Ducancelle A
    J Infect; 2020 Aug; 81(2):248-254. PubMed ID: 32413363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer.
    Wright TC; Denny L; Kuhn L; Pollack A; Lorincz A
    JAMA; 2000 Jan; 283(1):81-6. PubMed ID: 10632284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triage of women with ASCUS and LSIL on Pap smear reports: management by repeat Pap smear, HPV DNA testing, or colposcopy?
    Ferris DG; Wright TC; Litaker MS; Richart RM; Lorincz AT; Sun XW; Borgatta L; Buck H; Kramer L; Rubin R
    J Fam Pract; 1998 Feb; 46(2):125-34. PubMed ID: 9487318
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.